CDNA (CareDx) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDNA CareDx Inc CDNA
67 GF Score
Price $46.69
GF Value $25.09
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CareDx Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CDNA vs NEO, WGS, PSNL: Short Interest Comparison

For the Diagnostics & Research subindustry, CareDx's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareDx Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Short Interest distribution charts can be found below:

* The bar in red indicates where CareDx's Short Interest falls into.


CDNA
67GF Score
CareDx Inc CDNA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CareDx (CDNA) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of $46.69 is trading 86.1% above its estimated GF Value™ of $25.09. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for CDNA:

  • Short Interest:
  • GF Value™: $25.09 vs. price of $46.69 (86.1% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the CDNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CareDx Business Description

Other Exchanges 1K9:Germany
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
67GF Score

Get the complete analysis for CDNA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.69
Price
$25.09
GF Value